{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:26:56Z","timestamp":1786688816196,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have transformed cancer outcomes across multiple malignancies. However, emerging evidence suggests that thrombotic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE) are serious complications that may negatively affect survival. This study aims to determine their incidence, identify independent risk factors, and evaluate effects on outcomes and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed adult patients treated with ICIs at a tertiary academic center. Thrombotic events were classified as VTE or ATE occurring from ICI initiation through follow-up. Clinical, laboratory, and treatment-related variables were collected. Kaplan\u2013Meier methods and multivariable Cox proportional hazards models were used to evaluate survival impact and identify independent predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 750 patients treated with ICIs, 125 (16.6%) thrombotic events occurred over a median follow-up of 25 months. Of these events, 105 (84.0%) were VTE and 20 (16.0%) were ATE. Of all thrombotic events, 38% occurred within the first 6 months, 56% within 12 months, 67% within 18 months, and 74% within 24 months. Independent predictors of TE included prior VTE (HR 1.84, 95% CI 1.12\u20133.01; p = 0.015), lower baseline hemoglobin (HR 0.88, 95% CI 0.80\u20130.99; p = 0.036), and older age at immunotherapy initiation (HR 1.07 per year increase, 95% CI 1.04\u20131.11; p &amp;lt; 0.001).Thrombotic events were associated with significantly worse overall survival (OS) (log-rank p &amp;lt; 0.001) and remained independently associated with mortality in multivariable analysis (HR 2.55, 95% CI 1.89\u20133.43; p &amp;lt; 0.001). Additionally, prior thrombotic events (HR 1.86, 95% CI 1.29\u20132.69; p = 0.001) and a Khorana score \u22652 (HR 1.31, 95% CI 1.13-1.50, p&amp;lt;0.001) were independently associated with worse OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Thrombotic events are common in patients receiving ICIs and are independently associated with worse survival. Risk-based and personalized assessment of thrombotic events can help guide monitoring and management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1852772","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:31:50Z","timestamp":1786685510000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Thrombotic complications in patients treated with immune checkpoint inhibitors: a retrospective study of incidence, risk factors, and survival outcomes"],"prefix":"10.3389","volume":"17","author":[{"given":"Ali","family":"Awada","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ghais","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sary","family":"Faraj","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Tarhini","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Rizkallah","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Mashmoushi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souad Susan","family":"Sawaf","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Charbel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Haroun","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akel","family":"Khaled","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Madi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Kteich","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"El Mustapha","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hassan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Kreidieh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology: Current uses and future directions: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Tan","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70412","article-title":"The role of immune checkpoint inhibitors in cancer therapy: Mechanism and therapeutic advances","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm (2020)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00508-017-1285-9","article-title":"Review of cancer treatment with immune checkpoint inhibitors: Current concepts, expectations, limitations and pitfalls","volume":"130","author":"Thallinger","year":"2018","journal-title":"Wien Klin Wochenschr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2215543","article-title":"The correlation between the influencing factors and efficacy of immune checkpoint inhibitor therapy: An umbrella meta-analysis of randomized controlled trials","volume":"55","author":"Hu","year":"2023","journal-title":"Ann Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: A review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006072","article-title":"Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer","volume":"11","author":"Khorana","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.109243","article-title":"Thromboembolic events associated with immune checkpoint inhibitors in cancer patients: A Bayesian network meta-analysis","volume":"246","author":"Lin","year":"2025","journal-title":"Thromb Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6455","article-title":"Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study","volume":"12","author":"Zhu","year":"2023","journal-title":"Cancer Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103451","article-title":"Exploring the emerging association between immune checkpoint inhibitors and thrombosis","volume":"14","author":"Fawaz","year":"2025","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010761","article-title":"Immune checkpoint inhibitor-associated risk for venous thromboembolism: A comprehensive analysis","volume":"13","author":"Sussman","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.thromres.2021.06.018","article-title":"Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study","volume":"205","author":"Desch\u00eanes-Simard","year":"2021","journal-title":"Thromb Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321112","article-title":"Venous and arterial thrombosis in patients receiving immune checkpoint inhibitors","volume":"20","author":"van Lent","year":"2025","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30030230","article-title":"Immune checkpoint inhibitors-associated thrombosis: Incidence, risk factors and management","volume":"30","author":"Wang","year":"2023","journal-title":"Curr Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.09.038","article-title":"Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review","volume":"196","author":"Solinas","year":"2020","journal-title":"Thromb Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27041874","article-title":"Cancer-associated thrombosis in patients treated with immune checkpoint inhibitors","volume":"27","author":"Ilari","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2450\/2010.0066-10","article-title":"Risk factors for venous and arterial thrombosis","volume":"9","author":"Previtali","year":"2011","journal-title":"Blood Transfus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1099069","article-title":"Chronic anemia is associated with systemic endothelial dysfunction","volume":"10","author":"Chennupati","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15020411","article-title":"Anemia as a potent and underrecognized driver of venous thromboembolism: A systematic review","volume":"15","author":"Mansour","year":"2026","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2026.102894","article-title":"Risk factors for venous thromboembolism in older patients with Malignant solid tumors: A systematic review","volume":"17","author":"Hu","year":"2026","journal-title":"J Geriatr Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175512","article-title":"Aging and vascular disease: A multidisciplinary overview","volume":"12","author":"Maier","year":"2023","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/07357900802656681","article-title":"Venous thromboembolism (VTE) in patients with cancer: Epidemiology and risk factors","volume":"27","author":"Wun","year":"2009","journal-title":"Cancer Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.930797","article-title":"Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs fibronectin-EDA, S100\/calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways","volume":"9","author":"Quagliariello","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2016.10.010","article-title":"Blood coagulation in immunothrombosis-at the frontline of intravascular immunity","volume":"28","author":"Gaertner","year":"2016","journal-title":"Semin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14144926","article-title":"Venous thromboembolic events in cancer immunotherapy: A narrative review","volume":"14","author":"Fowler","year":"2025","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2021.12.018","article-title":"Neutrophil extracellular traps and cancer-associated thrombosis","volume":"213","author":"Rosell","year":"2022","journal-title":"Thromb Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02860-5","article-title":"Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: A study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group","volume":"24","author":"C\u00e1novas","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-021-00261-2","article-title":"A cross-sectional, multicenter, observational study to assess the prophylaxis of venous thromboembolism in Lebanese and Jordanian hospitals","volume":"19","author":"Hajj","year":"2021","journal-title":"Thromb J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:31:51Z","timestamp":1786685511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1852772"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1852772","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1852772"}}